Matthew P Fox1,2,3, Sophie J S Pascoe2, Amy N Huber2, Joshua Murphy2, Mokgadi Phokojoe4, Marelize Gorgens5, Sydney Rosen1,2, David Wilson5, Yogan Pillay4, Nicole Fraser-Hurt5. 1. Department of Global Health, Boston University School of Public Health, Boston, MA, USA. 2. Health Economics and Epidemiology Research Office, Department of Internal Medicine, Faculty of Health Sciences, School of Clinical Medicine, University of the Witwatersrand, Johannesburg, South Africa. 3. Department of Epidemiology, Boston University School of Public Health, Boston, MA, USA. 4. National Department of Health, Pretoria, South Africa. 5. The World Bank Group, Washington, DC, USA.
Abstract
BACKGROUND: As loss from HIV care is an ongoing challenge globally, interventions are needed for patients who don't achieve or maintain ART stability. The 2015 South African National Adherence Guidelines (AGL) for Chronic Diseases include two interventions targeted at unstable patients: early tracing of patients who miss visits (TRIC) and enhanced adherence counselling (EAC). METHODS: As part of a cluster-randomised evaluation at 12 intervention and 12 control clinics in four provinces, intervention sites implemented the AGL interventions, while control sites retained standard care. We report on outcomes of EAC for patients with an elevated viral load (>400 copies/ml) and for TRIC patients who missed a visit by >5 days. We estimated risk differences (RD) of 3 and 12-month viral resuppression (<400 copies/ml) and 12-month retention with cluster adjustment using generalised estimating equations and controlled for imbalances using difference-in-differences compared to all eligible in 2015, prior to intervention roll-out. RESULTS: For EAC, we had 358 intervention and 505 control site patients (61% female, median ART initiation CD4 count 154 cells/μl). We found no difference between arms in 3-month resuppression (RD: -1.7%; 95%CI: -4.3% to 0.9%), but <20% of patients had a repeat viral load within 3 months (19.8% intervention, 13.5% control). Including the entire clinic population eligible for EAC with a repeat viral load at all evaluation sites (n = 934), intervention sites showed a small increase in 3-month resuppression (28% vs. 25%, RD 3.0%; 95%CI: -2.7% to 8.8%). Adjusting for baseline differences increased the RD to 8.1% (95% CI: -0.1% to 17.2%). However, we found no differences in 12-month suppression (RD: 1.5%; 95% CI: -14.1% to 17.1% but suppression was low overall at 40%) or retention (RD: 2.8%; 95% CI: -7.5% to 13.2%). For TRIC, we enrolled 155 at intervention sites and 248 at control sites (44% >40 years, 67% female, median CD4 count 212 cells/μl). We found no difference between groups in return to care by 12 months (RD: -6.8%; 95% CI: -17.7% to 4.8%). During the study period, control sites continued to use tracing within standard care, however, potentially masking intervention effects. CONCLUSIONS: Enhanced adherence counselling showed no benefit over 12 months. Implementation of the tracing intervention under the new guidelines was similar to the standard of care. Interventions that aim to return unstable patients to care should incorporate active monitoring to determine if the interventions are effective.
RCT Entities:
BACKGROUND: As loss from HIV care is an ongoing challenge globally, interventions are needed for patients who don't achieve or maintain ART stability. The 2015 South African National Adherence Guidelines (AGL) for Chronic Diseases include two interventions targeted at unstable patients: early tracing of patients who miss visits (TRIC) and enhanced adherence counselling (EAC). METHODS: As part of a cluster-randomised evaluation at 12 intervention and 12 control clinics in four provinces, intervention sites implemented the AGL interventions, while control sites retained standard care. We report on outcomes of EAC for patients with an elevated viral load (>400 copies/ml) and for TRICpatients who missed a visit by >5 days. We estimated risk differences (RD) of 3 and 12-month viral resuppression (<400 copies/ml) and 12-month retention with cluster adjustment using generalised estimating equations and controlled for imbalances using difference-in-differences compared to all eligible in 2015, prior to intervention roll-out. RESULTS: For EAC, we had 358 intervention and 505 control site patients (61% female, median ART initiation CD4 count 154 cells/μl). We found no difference between arms in 3-month resuppression (RD: -1.7%; 95%CI: -4.3% to 0.9%), but <20% of patients had a repeat viral load within 3 months (19.8% intervention, 13.5% control). Including the entire clinic population eligible for EAC with a repeat viral load at all evaluation sites (n = 934), intervention sites showed a small increase in 3-month resuppression (28% vs. 25%, RD 3.0%; 95%CI: -2.7% to 8.8%). Adjusting for baseline differences increased the RD to 8.1% (95% CI: -0.1% to 17.2%). However, we found no differences in 12-month suppression (RD: 1.5%; 95% CI: -14.1% to 17.1% but suppression was low overall at 40%) or retention (RD: 2.8%; 95% CI: -7.5% to 13.2%). For TRIC, we enrolled 155 at intervention sites and 248 at control sites (44% >40 years, 67% female, median CD4 count 212 cells/μl). We found no difference between groups in return to care by 12 months (RD: -6.8%; 95% CI: -17.7% to 4.8%). During the study period, control sites continued to use tracing within standard care, however, potentially masking intervention effects. CONCLUSIONS: Enhanced adherence counselling showed no benefit over 12 months. Implementation of the tracing intervention under the new guidelines was similar to the standard of care. Interventions that aim to return unstable patients to care should incorporate active monitoring to determine if the interventions are effective.
Authors: Paul K Drain; Jienchi Dorward; Andrew Bender; Lorraine Lillis; Francesco Marinucci; Jilian Sacks; Anna Bershteyn; David S Boyle; Jonathan D Posner; Nigel Garrett Journal: Clin Microbiol Rev Date: 2019-05-15 Impact factor: 26.132
Authors: Forrest Toegel; Andrew M Rodewald; Matthew D Novak; Sarah Pollock; Meghan Arellano; Jeannie-Marie Leoutsakos; August F Holtyn; Kenneth Silverman Journal: AIDS Behav Date: 2021-11-16
Authors: Andrew D Kerkhoff; Kombatende Sikombe; Ingrid Eshun-Wilson; Izukanji Sikazwe; David V Glidden; Jake M Pry; Paul Somwe; Laura K Beres; Sandra Simbeza; Chanda Mwamba; Chama Bukankala; Cardinal Hantuba; Carolyn Bolton Moore; Charles B Holmes; Nancy Padian; Elvin H Geng Journal: PLoS Med Date: 2020-05-13 Impact factor: 11.069
Authors: Sophie J S Pascoe; Nancy A Scott; Rachel M Fong; Joshua Murphy; Amy N Huber; Aneesa Moolla; Mokgadi Phokojoe; Marelize Gorgens; Sydney Rosen; David Wilson; Yogan Pillay; Matthew P Fox; Nicole Fraser-Hurt Journal: J Int AIDS Soc Date: 2020-06 Impact factor: 5.396
Authors: Matthew P Fox; Sophie Pascoe; Amy N Huber; Joshua Murphy; Mokgadi Phokojoe; Marelize Gorgens; Sydney Rosen; David Wilson; Yogan Pillay; Nicole Fraser-Hurt Journal: PLoS Med Date: 2019-07-23 Impact factor: 11.069
Authors: Matthew D Hickey; James Ayieko; Dalsone Kwarisiima; Fredrick J Opel; Asiphas Owaraganise; Laura B Balzer; Gabriel Chamie; Vivek Jain; James Peng; Carol Camlin; Edwin D Charlebois; Craig R Cohen; Elizabeth A Bukusi; Moses R Kamya; Maya L Petersen; Diane V Havlir Journal: J Acquir Immune Defic Syndr Date: 2020-12-15 Impact factor: 3.771